{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T16:45:38Z","timestamp":1790613938913,"version":"4.1.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T00:00:00Z","timestamp":1754352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T00:00:00Z","timestamp":1754352000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Cerebrospinal fluid (CSF) \u03b1-synuclein (\u03b1-syn) seed amplification assays (SAAs) can detect Lewy body pathology (LBP) with high accuracy but are invasive and costly. To address these challenges, this study evaluated a two-step workflow combining prescreening via smell-function testing with confirmatory CSF \u03b1-syn SAA testing only in individuals with reduced smell, for predicting <jats:italic>postmortem<\/jats:italic> LBP status. Among 358 autopsied participants, the two-step workflow predicted brain LBP with high accuracy overall (94%), and within clinical subgroups (clinical parkinsonism=95%; clinical Alzheimer\u2019s disease [AD]=94%; clinically unimpaired [CU]=93%). It reduced the need for confirmatory CSF testing by 43% overall (23% clinical parkinsonism; 35% clinical AD; 80% CU). In an independent in vivo cohort (<jats:italic>N<\/jats:italic>=1209), the workflow predicted CSF \u03b1-syn SAA status with 79% accuracy and reduced CSF testing by 26%. This approach may reduce invasive CSF testing, alleviating patient burden and lowering healthcare costs.<\/jats:p>","DOI":"10.1038\/s41467-025-62458-7","type":"journal-article","created":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T11:20:45Z","timestamp":1754392845000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Two-step detection of Lewy body pathology via smell-function testing and CSF \u03b1-synuclein seed amplification"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-2759-9588","authenticated-orcid":false,"given":"Sophie E.","family":"Mastenbroek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6263-1762","authenticated-orcid":false,"given":"Lyduine E.","family":"Collij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6394-9940","authenticated-orcid":false,"given":"Jacob W.","family":"Vogel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Caldera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geidy E.","family":"Serrano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles H.","family":"Adler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-2921-6829","authenticated-orcid":false,"given":"Claudia Marina","family":"Vargiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9267-1930","authenticated-orcid":false,"given":"Sebastian","family":"Palmqvist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3543-3706","authenticated-orcid":false,"given":"Frederik","family":"Barkhof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9444-9524","authenticated-orcid":false,"given":"Piero","family":"Parchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas G.","family":"Beach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1584-7477","authenticated-orcid":false,"given":"Rik","family":"Ossenkoppele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8467-7286","authenticated-orcid":false,"given":"Oskar","family":"Hansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,5]]},"reference":[{"key":"62458_CR1","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/S1474-4422(23)00405-2","volume":"23","author":"T Simuni","year":"2024","unstructured":"Simuni, T. et al. A biological definition of neuronal \u03b1-synuclein disease: towards an integrated staging system for research. Lancet Neurol. 23, 178\u2013190 (2024).","journal-title":"Lancet Neurol."},{"key":"62458_CR2","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1080\/14737159.2024.2403073","volume":"24","author":"L Gaetani","year":"2024","unstructured":"Gaetani, L., Paolini Paoletti, F., Mechelli, A., Bellomo, G. & Parnetti, L. Research advancement in fluid biomarkers for Parkinson\u2019s disease. Expert Rev. Mol. Diagn. 24, 885\u2013898 (2024).","journal-title":"Expert Rev. Mol. Diagn."},{"key":"62458_CR3","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1002\/acn3.338","volume":"3","author":"G Fairfoul","year":"2016","unstructured":"Fairfoul, G. et al. Alpha-synuclein RT-QuIC in the CSF of patients with alpha-synucleinopathies. Ann. Clin. Transl. Neurol. 3, 812\u2013818 (2016).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"62458_CR4","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1038\/s41591-023-02450-0","volume":"29","author":"S Palmqvist","year":"2023","unstructured":"Palmqvist, S. et al. Cognitive effects of Lewy body pathology in clinically unimpaired individuals. Nat. Med. 29, 1971\u20131978 (2023).","journal-title":"Nat. Med."},{"key":"62458_CR5","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1038\/s41591-023-02449-7","volume":"29","author":"C Quadalti","year":"2023","unstructured":"Quadalti, C. et al. Clinical effects of Lewy body pathology in cognitively impaired individuals. Nat. Med. 29, 1964\u20131970 (2023).","journal-title":"Nat. Med."},{"key":"62458_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s43587-023-00471-5","volume":"3","author":"W Brum","year":"2023","unstructured":"Brum, W. et al. A two-step workflow based on plasma p-tau217 to screen for amyloid \u03b2 positivity with further confirmatory testing only in uncertain cases. Nat. Aging 3, 1\u201312 (2023).","journal-title":"Nat. Aging"},{"key":"62458_CR7","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1001\/jamaneurol.2023.4596","volume":"81","author":"N Mattsson-Carlgren","year":"2024","unstructured":"Mattsson-Carlgren, N. et al. Plasma biomarker strategy for selecting patients with Alzheimer disease for antiamyloid immunotherapies. JAMA Neurol. 81, 69\u201378 (2024).","journal-title":"JAMA Neurol."},{"key":"62458_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-46603-2","volume":"15","author":"WS Brum","year":"2024","unstructured":"Brum, W. S. et al. A blood-based biomarker workflow for optimal tau-PET referral in memory clinic settings. Nat. Commun. 15, 2311 (2024).","journal-title":"Nat. Commun."},{"key":"62458_CR9","doi-asserted-by":"publisher","first-page":"e0231720","DOI":"10.1371\/journal.pone.0231720","volume":"15","author":"TG Beach","year":"2020","unstructured":"Beach, T. G. et al. Severe hyposmia distinguishes neuropathologically confirmed dementia with Lewy bodies from Alzheimer\u2019s disease dementia. PLoS ONE 15, e0231720 (2020).","journal-title":"PLoS ONE"},{"key":"62458_CR10","doi-asserted-by":"publisher","DOI":"10.1002\/mdc3.14244","author":"C Tremblay","year":"2024","unstructured":"Tremblay, C. et al. Predicting post-mortem \u03b1-synuclein pathology by the combined presence of probable REM sleep behavior disorder and hyposmia. Mov. Disord. Clin. Pract. https:\/\/doi.org\/10.1002\/mdc3.14244 (2024).","journal-title":"Mov. Disord. Clin. Pract."},{"key":"62458_CR11","first-page":"19","volume":"19","author":"S Hasan","year":"2022","unstructured":"Hasan, S. et al. Olfactory dysfunction in incidental Lewy body disease and Parkinson\u2019s disease: an update. Innov. Clin. Neurosci. 19, 19\u201323 (2022).","journal-title":"Innov. Clin. Neurosci."},{"key":"62458_CR12","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/0031-9384(84)90269-5","volume":"32","author":"RL Doty","year":"1984","unstructured":"Doty, R. L., Shaman, P. & Dann, M. Development of the University of Pennsylvania Smell Identification Test: a standardized microencapsulated test of olfactory function. Physiol. Behav. 32, 489\u2013502 (1984).","journal-title":"Physiol. Behav."},{"key":"62458_CR13","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1111\/neup.12189","volume":"35","author":"TG Beach","year":"2015","unstructured":"Beach, T. G. et al. Arizona study of aging and neurodegenerative disorders and brain and body donation program. Neuropathology 35, 354\u2013389 (2015).","journal-title":"Neuropathology"},{"key":"62458_CR14","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1093\/brain\/awab099","volume":"144","author":"S Spina","year":"2021","unstructured":"Spina, S. et al. Comorbid neuropathological diagnoses in early versus late-onset Alzheimer\u2019s disease. Brain 144, 2186\u20132198 (2021).","journal-title":"Brain"},{"key":"62458_CR15","doi-asserted-by":"publisher","first-page":"145","DOI":"10.3389\/fnins.2020.00145","volume":"14","author":"L Brozzetti","year":"2020","unstructured":"Brozzetti, L. et al. Neurodegeneration-associated proteins in human olfactory neurons collected by nasal brushing. Front. Neurosci. 14, 145 (2020).","journal-title":"Front. Neurosci."},{"key":"62458_CR16","doi-asserted-by":"publisher","first-page":"e0243535","DOI":"10.1371\/journal.pone.0243535","volume":"15","author":"MJ Sedghizadeh","year":"2020","unstructured":"Sedghizadeh, M. J. et al. Olfactory response as a marker for Alzheimer\u2019s disease: Evidence from perceptual and frontal lobe oscillation coherence deficit. PLoS ONE 15, e0243535 (2020).","journal-title":"PLoS ONE"},{"key":"62458_CR17","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.neurobiolaging.2006.11.014","volume":"29","author":"J Djordjevic","year":"2008","unstructured":"Djordjevic, J., Jones-Gotman, M., De Sousa, K. & Chertkow, H. Olfaction in patients with mild cognitive impairment and Alzheimer\u2019s disease. Neurobiol. Aging 29, 693\u2013706 (2008).","journal-title":"Neurobiol. Aging"},{"key":"62458_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s40478-022-01388-7","volume":"10","author":"S Hall","year":"2022","unstructured":"Hall, S. et al. Performance of \u03b1Synuclein RT-QuIC in relation to neuropathological staging of Lewy body disease. Acta Neuropathol. Commun. 10, 90 (2022).","journal-title":"Acta Neuropathol. Commun."},{"key":"62458_CR19","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s40478-021-01175-w","volume":"9","author":"C Bargar","year":"2021","unstructured":"Bargar, C. et al. Streamlined alpha-synuclein RT-QuIC assay for various biospecimens in Parkinson\u2019s disease and dementia with Lewy bodies. Acta Neuropathol. Commun. 9, 62 (2021).","journal-title":"Acta Neuropathol. Commun."},{"key":"62458_CR20","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.1002\/acn3.50897","volume":"6","author":"M Bongianni","year":"2019","unstructured":"Bongianni, M. et al. \u03b1-Synuclein RT-QuIC assay in cerebrospinal fluid of patients with dementia with Lewy bodies. Ann. Clin. Transl. Neurol. 6, 2120\u20132126 (2019).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"62458_CR21","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s00401-020-02160-8","volume":"140","author":"M Rossi","year":"2020","unstructured":"Rossi, M. et al. Ultrasensitive RT-QuIC assay with high sensitivity and specificity for Lewy body-associated synucleinopathies. Acta Neuropathol. 140, 49\u201362 (2020).","journal-title":"Acta Neuropathol."},{"key":"62458_CR22","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1002\/ana.26453","volume":"92","author":"MR Arnold","year":"2022","unstructured":"Arnold, M. R. et al. \u03b1-synuclein seed amplification in CSF and brain from patients with different brain distributions of pathological \u03b1-synuclein in the context of co-pathology and non-LBD diagnoses. Ann. Neurol. 92, 650\u2013662 (2022).","journal-title":"Ann. Neurol."},{"key":"62458_CR23","doi-asserted-by":"publisher","first-page":"5114","DOI":"10.1002\/alz.13858","volume":"20","author":"D Tosun","year":"2024","unstructured":"Tosun, D. et al. A cross-sectional study of \u0152\u00b1-synuclein seed amplification assay in Alzheimer\u2019s disease neuroimaging initiative: Prevalence and associations with Alzheimer\u2019s disease biomarkers and cognitive function. Alzheimers Dement. 20, 5114\u20135131 (2024).","journal-title":"Alzheimers Dement."},{"key":"62458_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-52299-1","volume":"15","author":"LE Collij","year":"2024","unstructured":"Collij, L. E. et al. Lewy body pathology exacerbates brain hypometabolism and cognitive decline in Alzheimer\u2019s disease. Nat. Commun. 15, 8061 (2024).","journal-title":"Nat. Commun."},{"key":"62458_CR25","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1007\/s00401-023-02663-0","volume":"147","author":"GM Bentivenga","year":"2024","unstructured":"Bentivenga, G. M. et al. Performance of a seed amplification assay for misfolded alpha-synuclein in cerebrospinal fluid and brain tissue in relation to Lewy body disease stage and pathology burden. Acta Neuropathol. 147, 18 (2024).","journal-title":"Acta Neuropathol."},{"key":"62458_CR26","doi-asserted-by":"publisher","first-page":"3334","DOI":"10.1002\/alz.13799","volume":"20","author":"N Samudra","year":"2024","unstructured":"Samudra, N. et al. Clinicopathological correlation of cerebrospinal fluid alpha-synuclein seed amplification assay in a behavioral neurology autopsy cohort. Alzheimers Dement. 20, 3334\u20133341 (2024).","journal-title":"Alzheimers Dement."},{"key":"62458_CR27","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1002\/acn3.52034","volume":"11","author":"MJ Plastini","year":"2024","unstructured":"Plastini, M. J. et al. Multiple biomarkers improve diagnostic accuracy across Lewy body and Alzheimer\u2019s disease spectra. Ann. Clin. Transl. Neurol. 11, 1197\u20131210 (2024).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"62458_CR28","doi-asserted-by":"publisher","first-page":"4351","DOI":"10.1002\/alz.13818","volume":"20","author":"J Levin","year":"2024","unstructured":"Levin, J. et al. \u03b1-Synuclein seed amplification assay detects Lewy body co-pathology in autosomal dominant Alzheimer\u2019s disease late in the disease course and dependent on Lewy pathology burden. Alzheimers Dement. 20, 4351\u20134365 (2024).","journal-title":"Alzheimers Dement."},{"key":"62458_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/0361073X.2022.2160597","volume":"50","author":"M Alotaibi","year":"2024","unstructured":"Alotaibi, M. et al. Olfactory dysfunction associated with cognitive decline in an elderly population. Exp. Aging Res. 50, 1\u201316 (2024).","journal-title":"Exp. Aging Res."},{"key":"62458_CR30","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.jns.2012.08.028","volume":"323","author":"M Barresi","year":"2012","unstructured":"Barresi, M. et al. Evaluation of olfactory dysfunction in neurodegenerative diseases. J. Neurol. Sci. 323, 16\u201324 (2012).","journal-title":"J. Neurol. Sci."},{"key":"62458_CR31","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/B978-0-444-63855-7.00020-4","volume":"164","author":"RL Doty","year":"2019","unstructured":"Doty, R. L. & Hawkes, C. H. Chemosensory dysfunction in neurodegenerative diseases. Handb. Clin. Neurol. 164, 325\u2013360 (2019).","journal-title":"Handb. Clin. Neurol."},{"key":"62458_CR32","doi-asserted-by":"publisher","unstructured":"Fatuzzo, I. et al. Neurons, nose, and neurodegenerative diseases: olfactory function and cognitive impairment. Int. J. Mol. Sci. 24, https:\/\/doi.org\/10.3390\/ijms24032117 (2023).","DOI":"10.3390\/ijms24032117"},{"key":"62458_CR33","doi-asserted-by":"publisher","first-page":"493","DOI":"10.3109\/13547500903108423","volume":"14","author":"AE Roher","year":"2009","unstructured":"Roher, A. E. et al. Proteomics-derived cerebrospinal fluid markers of autopsy-confirmed Alzheimer\u2019s disease. Biomarkers 14, 493\u2013501 (2009).","journal-title":"Biomarkers"},{"key":"62458_CR34","doi-asserted-by":"publisher","first-page":"19","DOI":"10.4137\/BMI.S11422","volume":"8","author":"C Maarouf","year":"2013","unstructured":"Maarouf, C. et al. Quantitative appraisal of ventricular cerebrospinal fluid biomarkers in neuropathologically diagnosed Parkinson\u2019s disease cases lacking Alzheimer\u2019s disease pathology. Biomark. Insights 8, 19\u201328 (2013).","journal-title":"Biomark. Insights"},{"key":"62458_CR35","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1002\/mds.25555","volume":"28","author":"PA Lewitt","year":"2013","unstructured":"Lewitt, P. A. et al. 3-hydroxykynurenine and other Parkinson\u2019s disease biomarkers discovered by metabolomic analysis. Mov. Disord. 28, 1653\u20131660 (2013).","journal-title":"Mov. Disord."},{"key":"62458_CR36","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1179\/1743132812Y.0000000063","volume":"34","author":"CL Maarouf","year":"2012","unstructured":"Maarouf, C. L. et al. Cerebrospinal fluid biomarkers of neuropathologically diagnosed Parkinson\u2019s disease subjects. Neurol. Res. 34, 669\u2013676 (2012).","journal-title":"Neurol. Res."},{"key":"62458_CR37","doi-asserted-by":"publisher","first-page":"e94839","DOI":"10.1371\/journal.pone.0094839","volume":"9","author":"K Burgos","year":"2014","unstructured":"Burgos, K. et al. Profiles of extracellular miRNA in cerebrospinal fluid and serum from patients with Alzheimer\u2019s and Parkinson\u2019s diseases correlate with disease status and features of pathology. PLoS ONE 9, e94839 (2014).","journal-title":"PLoS ONE"},{"key":"62458_CR38","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1212\/WNL.0000000000002151","volume":"85","author":"S Janelidze","year":"2015","unstructured":"Janelidze, S. et al. Increased CSF biomarkers of angiogenesis in Parkinson disease. Neurology 85, 1834\u20131842 (2015).","journal-title":"Neurology"},{"key":"62458_CR39","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.jneumeth.2010.06.017","volume":"191","author":"AH Simonsen","year":"2010","unstructured":"Simonsen, A. H. et al. Proteomic investigations of the ventriculo-lumbar gradient in human CSF. J. Neurosci. Methods 191, 244\u2013248 (2010).","journal-title":"J. Neurosci. Methods"},{"key":"62458_CR40","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.pneurobio.2011.09.005","volume":"95","author":"K Marek","year":"2011","unstructured":"Marek, K. et al. The Parkinson progression marker initiative (PPMI). Prog. Neurobiol. 95, 629\u2013635 (2011).","journal-title":"Prog. Neurobiol."},{"key":"62458_CR41","doi-asserted-by":"publisher","first-page":"2490","DOI":"10.1212\/WNL.94.15_supplement.2490","volume":"94","author":"K Marek","year":"2020","unstructured":"Marek, K. et al. PPMI 2. O new science\/new cohorts-transforming PPMI (2490). Neurology 94, 2490 (2020).","journal-title":"Neurology"},{"key":"62458_CR42","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1038\/s41596-022-00787-3","volume":"18","author":"L Concha-Marambio","year":"2023","unstructured":"Concha-Marambio, L., Pritzkow, S., Shahnawaz, M., Farris, C. M. & Soto, C. Seed amplification assay for the detection of pathologic alpha-synuclein aggregates in cerebrospinal fluid. Nat. Protoc. 18, 1179\u20131196 (2023).","journal-title":"Nat. Protoc."},{"key":"62458_CR43","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/S1474-4422(23)00109-6","volume":"22","author":"A Siderowf","year":"2023","unstructured":"Siderowf, A. et al. Assessment of heterogeneity among participants in the Parkinson\u2019s Progression Markers Initiative cohort using \u03b1-synuclein seed amplification: a cross-sectional study. Lancet Neurol. 22, 407\u2013417 (2023).","journal-title":"Lancet Neurol."},{"key":"62458_CR44","doi-asserted-by":"publisher","DOI":"10.1186\/s40478-021-01282-8","volume":"9","author":"MJ Russo","year":"2021","unstructured":"Russo, M. J. et al. High diagnostic performance of independent alpha-synuclein seed amplification assays for detection of early Parkinson\u2019s disease. Acta Neuropathol. Commun. 9, 179 (2021).","journal-title":"Acta Neuropathol. Commun."},{"key":"62458_CR45","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1002\/mds.27646","volume":"34","author":"UJ Kang","year":"2019","unstructured":"Kang, U. J. et al. Comparative study of cerebrospinal fluid \u03b1-synuclein seeding aggregation assays for diagnosis of Parkinson\u2019s disease. Mov. Disord. 34, 536\u2013544 (2019).","journal-title":"Mov. Disord."},{"key":"62458_CR46","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/ncb748","volume":"4","author":"H Fujiwara","year":"2002","unstructured":"Fujiwara, H. et al. \u03b1-Synuclein is phosphorylated in synucleinopathy lesions. Nat. Cell Biol. 4, 160\u2013164 (2002).","journal-title":"Nat. Cell Biol."},{"key":"62458_CR47","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.expneurol.2012.11.020","volume":"240","author":"DG Walker","year":"2013","unstructured":"Walker, D. G. et al. Changes in properties of serine 129 phosphorylated \u03b1-synuclein with progression of Lewy-type histopathology in human brains. Exp. Neurol. 240, 190\u2013204 (2013).","journal-title":"Exp. Neurol."},{"key":"62458_CR48","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s00401-020-02255-2","volume":"141","author":"J Attems","year":"2021","unstructured":"Attems, J. et al. Neuropathological consensus criteria for the evaluation of Lewy pathology in post-mortem brains: a multi-centre study. Acta Neuropathol. 141, 159\u2013172 (2021).","journal-title":"Acta Neuropathol."},{"key":"62458_CR49","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1212\/01.wnl.0000187889.17253.b1","volume":"65","author":"IG McKeith","year":"2005","unstructured":"McKeith, I. G. et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 65, 1863\u20131872 (2005).","journal-title":"Neurology"},{"key":"62458_CR50","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1007\/s00401-004-0950-z","volume":"109","author":"DW Dickson","year":"2005","unstructured":"Dickson, D. W. Required techniques and useful molecular markers in the neuropathologic diagnosis of neurodegenerative diseases. Acta Neuropathol. 109, 14\u201324 (2005).","journal-title":"Acta Neuropathol."},{"key":"62458_CR51","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1016\/S1474-4422(09)70238-8","volume":"8","author":"DW Dickson","year":"2009","unstructured":"Dickson, D. W. et al. Neuropathological assessment of Parkinson\u2019s disease: refining the diagnostic criteria. Lancet Neurol. 8, 1150\u20131157 (2009).","journal-title":"Lancet Neurol."},{"key":"62458_CR52","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1001\/archneur.56.1.33","volume":"56","author":"DJ Gelb","year":"1999","unstructured":"Gelb, D. J., Oliver, E. & Gilman, S. Diagnostic criteria for Parkinson disease. Arch. Neurol. 56, 33\u201339 (1999).","journal-title":"Arch. Neurol."},{"key":"62458_CR53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jalz.2011.10.007","volume":"8","author":"BT Hyman","year":"2012","unstructured":"Hyman, B. T. et al. National Institute on Aging-Alzheimer\u2019s Association guidelines for the neuropathologic assessment of Alzheimer\u2019s disease. Alzheimers Dement. 8, 1\u201313 (2012).","journal-title":"Alzheimers Dement."},{"key":"62458_CR54","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s00401-011-0845-8","volume":"122","author":"IR Mackenzie","year":"2011","unstructured":"Mackenzie, I. R. et al. A harmonized classification system for FTLD-TDP pathology. Acta Neuropathol. 122, 111\u2013113 (2011).","journal-title":"Acta Neuropathol."},{"key":"62458_CR55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00401-011-0910-3","volume":"123","author":"TJ Montine","year":"2012","unstructured":"Montine, T. J. et al. National Institute on Aging-Alzheimer\u2019s Association guidelines for the neuropathologic assessment of Alzheimer\u2019s disease: a practical approach. Acta Neuropathol. 123, 1\u201311 (2012).","journal-title":"Acta Neuropathol."},{"key":"62458_CR56","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1212\/WNL.43.2.250","volume":"43","author":"GC Rom\u00e1n","year":"1993","unstructured":"Rom\u00e1n, G. C. et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 43, 250\u2013260 (1993).","journal-title":"Neurology"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-62458-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-62458-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-62458-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T18:43:33Z","timestamp":1757357013000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-62458-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,5]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["62458"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-62458-7","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,5]]},"assertion":[{"value":"21 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"O.H. is an employee of Eli Lilly and Lund University, and he has previously acquired research support (for Lund University) from AVID Radiopharmaceuticals, Biogen, C2N Diagnostics, Eli Lilly, Eisai, Fujirebio, GE Healthcare, and Roche. In the past 2 years, he has received consultancy\/speaker fees from Alzpath, BioArctic, Biogen, Bristol Meyer Squibb, Eisai, Eli Lilly, Fujirebio, Merck, Novartis, Novo Nordisk, Roche, Sanofi and Siemens. L.E.C. has received research support from GE Healthcare (paid to institution). SP has acquired research support (for the institution) from Avid and ki elements through ADDF. In the past 2 years, he has received consultancy\/speaker fees from Bioartic, Biogen, Esai, Eli Lilly, Novo Nordisk, and Roche. F.B. acts as a consultant for Biogen-Idec, IXICO, Merck-Serono, Novartis, Combinostics, and Roche. He has received grants, or grants are pending, from the Amyloid Imaging to Prevent Alzheimer\u2019s Disease (AMYPAD) initiative, the Biomedical Research Centre at University College London Hospitals, the Dutch MS Society, ECTRIMS\u2013MAGNIMS, EU-H2020, the Dutch Research Council (NWO), the UK MS Society, and the National Institute for Health Research, University College London. He has received payments for the development of educational presentations from Ixico and his institution from Biogen-Idec and Merck. He is on the editorial board of Radiology, European Neuroradiology, Multiple Sclerosis Journal, and Neurology. Is on the board of directors of Queen Square Analytics. R.O. has received research support from Avid Radiopharmaceuticals, has given lectures in symposia sponsored by GE Healthcare and is an editorial board member of Alzheimer\u2019s Research & Therapy and the European Journal of Nuclear Medicine and Molecular Imaging. T.G.B. is a consultant for Aprinoia Therapeutics, Biogen and Avid Radiopharmaceuticals. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7182"}}